Pharmaxis Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMXSF research report →
Price Chart
About the company
Pharmaxis Ltd, an Australian biopharmaceutical company established in 1998 and headquartered in Frenchs Forest, specializes in the global research, development, and commercialization of therapeutic products for fibrotic and inflammatory diseases. Its business is organized into two main divisions: the Mannitol Respiratory Business and New Drug Development. The company currently markets Bronchitol, an inhaled dry powder medication for the treatment of cystic fibrosis, and Aridol, a diagnostic tool used to detect hyper-responsive airways and assist in the diagnosis and management of asthma.
- CEO
- Gary Jonathan Phillips
- IPO
- 2010
- Employees
- 27
- HQ
- Frenchs Forest, NSW, AU
Get TickerSpark's AI analysis on PMXSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.04M
- P/E
- -4.72
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 2.29
- EV/EBITDA
- -1.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.92%
- ROIC
- -122.77%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-146,640+5.2%
- Op Income
- $-19,874,000
- Net Income
- $-7,919,000+47.7%
- EPS
- $-0.00+75.3%
- OCF Growth
- +23.3%
- FCF Growth
- +23.3%
- 52W High
- $0.03
- 52W Low
- $0.03
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- 0.27
- RSI (14)
- 0
- Avg Volume
- 98.28K
No earnings-call transcripts are available for PMXSF yet.
- Free Float
- 33.0%
- Shares Outstanding
- 1.19B
- Float Shares
- 394.30M
Our PMXSF coverage
Recent articles, reports, and earnings notes.
No research on PMXSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMXSF report →Syntara Limited (PMXSF) Q4 2026 Earnings Call Transcript
seekingalpha.com · Jul 27
Syntara Limited (PMXSF) Discusses Preliminary Phase II Results for SNT-4728 in Isolated REM Sleep Behavior Disorder Transcript
seekingalpha.com · Jul 6
Syntara Limited (PMXSF) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com · Jun 22
Syntara Limited (PMXSF) Shareholder/Analyst Call Transcript
seekingalpha.com · Jun 1
Syntara Limited (PMXSF) Shareholder/Analyst Call Transcript
seekingalpha.com · Apr 30
Syntara Limited (PMXSF) Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates Transcript
seekingalpha.com · Feb 3
Syntara Limited (PMXSF) Discusses Progress and Future Plans for Skin Scarring Program Transcript
seekingalpha.com · Nov 26
Syntara Limited (PMXSF) Shareholder/Analyst Call Transcript
seekingalpha.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.